Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction

S. Jarius · D. Wilken · J. Haas · K. Ruprecht · L. Komorowski · B. Wildemann

Received: 8 January 2021 / Revised: 11 February 2021 / Accepted: 13 February 2021 / Published online: 26 March 2021
© The Author(s) 2021

Abstract

Background A positive MRZ reaction, as defined by intrathecal IgG production against at least two of its constituents, measles virus (M), rubella virus (R) and varicella zoster virus (Z), is detectable in ~63% of patients with multiple sclerosis (MS) and is currently considered the laboratory marker with the highest specificity and positive likelihood ratio for MS. However, M, R and Z are only the most well-established constituents of a broader intrathecal humoral immune response in MS.

Objective To identify additional anti-microbial antibodies inclusion of which in the classical MRZ panel may result in increased sensitivity without compromising the marker’s high specificity for MS.

Methods We determined the antibody indices (AIs) for 11 viral and bacterial agents (M, R, Z, herpes simplex virus, Epstein–Barr virus, mumps virus, cytomegalovirus, parvovirus B19, Bordetella pertussis, Corynebacterium diphtheriae, and Clostridium tetani) in paired cerebrospinal fluid and serum samples from patients with MS and disease controls.

Results A positive ‘classical’ MRZ reaction was found in 17/26 (65.4%) MS patients. The five most frequently positive AIs among patients with MS were M (76.9%), Z (61.5%), R (57.7%), parvovirus B19 (42.3%), and mumps (28%). Addition of parvovirus B19 and mumps virus to the MRZ panel resulted in an increase in sensitivity in the MS group from 65.4% to 73.1%, with 22% of the initially MRZ-negative patients exhibiting a de novo-positive response. The extended MRZ panel (‘MRZplus’) distinguished sharply between MS (≥ 3 AIs in 90% of all positives) and controls (varying diagnoses, from migraine to vasculitis; 0-1 AIs; p < 0.000001). The highest median AI in the MS group was found for parvovirus B19 (3.97), followed by measles virus (2.79).

Conclusion Inclusion of parvovirus B19 and mumps virus in the test panel resulted in an increase in the sensitivity and discriminatory power of MRZ. Our results provide a strong rational for prospective studies investigating the role of extended MRZ panels in the differential diagnosis of MS.

Keywords Multiple sclerosis · MRZ reaction · Polyspecific intrathecal humoral immune response · Parvovirus B19 · Mumps virus · Measles virus · Rubella virus · Varicella zoster virus · Herpes simplex virus · Epstein–Barr virus · Cytomegalovirus · Antibody index

Introduction

Intrathecal production of antibodies to measles virus (M), rubella virus (R) and varicella zoster virus (VZV, Z), the so-called MRZ reaction (MRZR), as defined by the presence of a positive antibody index (AI) to at least two of its three constituents M, R and Z, is the laboratory marker with the highest specificity and positive likelihood ratio (LR) for MS known so far [8, 26]. However, as a limitation, only around 63% of patients with bona fide MS display a positive MRZR
patients with MS and disease controls. Of the 17 MS samples positive for the classical MRZR, 12 (71%) were positive for at least one of the additional AIs tested \((8 \times B [3 \times B, 2 \times B + U, 1 \times B + E + U, 1 \times B + H, 1 \times B + U + T], 3 \times T [2 \times T, 1 \times E + T], 1 \times U]\), corroborating the notion that the spectrum of the polyspecific humoral immune response in MS is indeed broader than just M, R and Z (median 1.5 additional AIs, range 0–3 in those positive for the classical MRZR) and suggesting that it may particularly frequently include parvovirus B19. As a limitation, four MRZ-positive MS patients could not be tested for all AIs due to a lack of material, which leaves the possibility that the real prevalence of additional positive AIs might even be higher and the spectrum of possible AI combinations even broader than reported here.
Of those MS patients with a negative classical MRZR, three (33%) were positive for one or more of the additional positive AIs, with B again prevailing (1 × B, 1 × B + U, 1 × B + E + U), resulting in a de novo positive (i.e., bi- or trispecific) reaction in two patients (1 × M + B + E + U, 1 × B + U) and thus in an increase in sensitivity in the MS group from 65.4% (17/26) to 73.1% (19/26). By contrast, none of the other additional AIs tested (D, T, P, H, C, E) resulted in an increase in sensitivity.

If all patients with MS are considered, 15/26 (58%) were positive for at least one (median 2 [range 1–3]) of the ‘additional’ AIs tested and 23/26 (89%) for at least one of the 11 AIs tested in total (median 4 [range 1–5]); in 3 patients none of the 11 AIs was positive.

As a drawback, inclusion of some of the additional AIs in the panel resulted in a decline in specificity, with four controls positive for at least one of the additional AIs and two of them, who had been MRZ-negative based on the original panel consisting of M, R and Z, displaying a bi- or trispecific reaction. However, when restricting the panel to MRZ + B + U, a positive (i.e., at least bispecific) reaction was observed in none of the control patients. None of the controls exhibited an intrathecal response to either M, R or Z, corroborating the high specificity of the original panel for MS. The difference between the MS and the control group regarding the frequency of a positive MRZ, MRZB or MRZBU reaction, as defined by a bi- or trispecific response, was highly significant (p < 0.000001, Mann–Whitney U test, irrespective of whether the single steroid-treated control patient was included or not).

### Table 1 Frequency of positive antibody indices (AI) for measles virus (M), rubella virus (R), varicella zoster virus (V), herpes simplex virus (H), Epstein Barr virus (E), mumps virus (U), cytomegalovirus (C), parvovirus B19 (B), Bordetella pertussis (P), Corynebacterium diphtheriae (D) and Clostridium tetani (T) in matched CSF/serum pairs from patients with MS and disease controls

| AI      | MS   | Controls | Controls vs. MS |
|---------|------|----------|-----------------|
| M       | 20/26 (76.9%) | 0/26 (0%) | p < 0.0000001  |
| R       | 15/26 (57.7%) | 0/26 (0%) | p < 0.0000001  |
| Z       | 16/26 (61.5%) | 0/26 (0%) | p < 0.0000001  |
| B       | 11/26 (42.3%) | 0/26 (0%) | p < 0.0000003  |
| H       | 1/22 (4.5%)  | 3/15 (20%) | n.d.            |
| E       | 3/22 (13.6%) | 1/24 (4.2%) | n.d.            |
| C       | 0/22 (0%)    | 2/15 (13.3%) | n.d.            |
| U       | 7/25 (28%)   | 1/23 (4.3%) | n.d.            |
| P       | 0/22 (0%)    | 0/15 (0%)   | n.d.            |
| D       | 0/22 (0%)    | 0/15 (0%)   | n.d.            |
| T       | 4/22 (18.2%) | 1/15 (6.7%) | n.d.            |

### Table 2 MRZ, MRZB and MRZBU reaction in matched CSF/serum samples from patients with MS and disease controls

| AI panel               | MS   | Controls | Controls vs. MS |
|------------------------|------|----------|-----------------|
| MRZ                    | 17/26 (65.4%) | 0/26 (0%) | p < 0.0000001  |
| M + R + Z              | 13/26 (50%)  | 0/26 (0%) |                 |
| M + R                  | 2/26 (7.7%)  | 0/26 (0%) |                 |
| M + Z                  | 2/26 (7.7%)  | 0/26 (0%) |                 |
| R + Z                  | 0/26 (0%)    | 0/26 (0%) |                 |
| MRZB                   | 18/26 (69.2%) | 0/26 (0%) | p < 0.0000001  |
| M + R + Z + B          | 4/26 (15.4%) | 0/26 (0%) |                 |
| M + R + Z              | 9/26 (34.6%) | 0/26 (0%) |                 |
| M + R + B              | 2/26 (7.7%)  | 0/26 (0%) |                 |
| M + Z + B              | 2/26 (7.7%)  | 0/26 (0%) |                 |
| R + Z + B              | 0/26 (0%)    | 0/26 (0%) |                 |
| M + B                  | 1/26 (3.8%)  | 0/26 (0%) |                 |
| M + R                  | 0/26 (0%)    | 0/26 (0%) |                 |
| M + Z                  | 0/26 (0%)    | 0/26 (0%) |                 |
| R + B                  | 0/26 (0%)    | 0/26 (0%) |                 |
| R + Z                  | 0/26 (0%)    | 0/26 (0%) |                 |
| Z + B                  | 0/26 (0%)    | 0/26 (0%) |                 |
| MRZBU                  | 19/25 (76%)  | 0/23 (0%) | p < 0.0000001  |
| M + R + Z + B + U      | 2/25 (8%)    | 0/23 (0%) |                 |
| M + R + Z + B          | 2/25 (8%)    | 0/23 (0%) |                 |
| M + R + Z + U          | 1/25 (4%)    | 0/23 (0%) |                 |
| M + R + B + U          | 1/25 (4%)    | 0/23 (0%) |                 |
| M + Z + B + U          | 1/25 (4%)    | 0/23 (0%) |                 |
| R + Z + B + U          | 0/25 (0%)    | 0/23 (0%) |                 |
| M + R + Z              | 8/25 (32%)   | 0/23 (0%) |                 |
| M + R + B              | 1/25 (4%)    | 0/23 (0%) |                 |
| M + R + U              | 0/25 (0%)    | 0/23 (0%) |                 |
| M + Z + B              | 1/25 (4%)    | 0/23 (0%) |                 |
| Z + B + U              | 0/25 (0%)    | 0/23 (0%) |                 |
| R + Z + B              | 0/25 (0%)    | 0/23 (0%) |                 |
| R + Z                  | 0/25 (0%)    | 0/23 (0%) |                 |
| Z + B                  | 0/25 (0%)    | 0/23 (0%) |                 |
| B + U                  | 1/25 (4%)    | 0/23 (0%) |                 |

### Notes

1. Borderline positive result in a single control patient (1.55; cut-off 1.5)

### References

AI antibody index, M measles virus, R rubella virus, V varicella zoster virus, B parvovirus B19, U mumps virus
A single (MRZBU-negative) control patient showed an isolated borderline positive AI for mumps (1.55; cut-off 1.5). We therefore tested whether the use of a more conservative cut-off for AI positivity would result in a decrease in sensitivity. When applying a cut-off of 1.6 or 1.7 for all AIs, the sensitivity of the extended MRZB or MRZBU panel remained unaltered and none of the controls exhibited a positive AI for parvovirus B19 or mumps virus (not shown).

Cross-reactivity between *Herpesviridae* is a potential issue, since it would result in false-positive bi- or multispecific responses. Overall, 3/37 (8.1%) patients tested for Z, H, E and C reacted against at least two of these four herpes viruses (2×MS; 1×disease control): one Z-AI-positive MS sample showed a positive H-AI and one a positive E-AI; in addition, a single patient with suspected cerebral vasculitis in the control group showed a positive intrathecal response to H, E and C.

Of note, all 4 MS patients who had displayed a bispecific reaction based on the classical MRZ panel showed a trispecific reaction after inclusion of B and U in the diagnostic panel and 17 of all 19 (90%) MRZplus-positive MS patients had at least a trispecific reaction (10×3 AIs, 5×4 AIs, 2×5 AIs), resulting in a more distinct discrimination between controls (0–1 AI) and MS patients (mostly 3 or more AIs).

No significant correlation between AI values and age at the time of LP was found, neither if all AIs nor if only positive AIs are considered. Moreover, the median age did not differ among MRZplus-positive and MRZplus-negative MS patients (48 years in both subgroups).

Median AIs for M, R, Z and B differed significantly between patients with MS and disease controls (*p* < 0.0001; Kruskal–Wallis) (Fig. 1). Of note, the highest median AI in the MS group was found for parvovirus B19 (AI = 3.97), followed by measles virus (AI = 2.79) (Fig. 1).

**Discussion**

This study is one of the largest performed so far on the intrathecal antimicrobial immune response in MS. Investigating a panel of eight additional antimicrobial AIs, we identified intrathecally produced antibodies to parvovirus B19 and mumps virus as novel promising markers for MS. Especially, addition of parvovirus B19 to the classical MRZ panel could help to increase the sensitivity of the MRZ reaction without compromising its specificity. Of further note, mumps virus was positive in 7/25 (28%) MS patients but only in a single control patient, who exhibited a borderline result (AI = 1.55; cut-off 1.5) (Table 1), rendering mumps virus another potentially interesting marker. In accordance with the latter finding, Sindic (1998) detected OCBs to M, R, Z and mumps virus in 18/18 patients with MS using an antigen-driven capillary blot technique, 15 of whom (83%) displayed a bi- or trispecific reaction [5, 31]. Applying a
slightly more conservative AI cut-off (1.6 or 1.7 instead of 1.5) resulted in 100% specificity of the extended panel (tentatively termed ‘MRZplus’) without causing a decline in sensitivity. This should be taken into account in future studies. As the MRZ test is mainly used as a ‘rule-in test’ rather than as a ‘rule-out test’ in MS, high specificity if of utmost importance.

It is of interest that a few of the control patients showed a monospecific intrathecal immune response to herpes viruses: a positive H-AI was noted in two patients with migraine and a positive C-AI in a patient with non-classified “cephalgia”. Although not likely, we cannot formally rule out that headache was related to herpes virus infection in these cases, since no polymerase chain reaction (PCR) was performed and the virus-specific intrathecal IgG fraction, F(s) [7, 21] was not determined due to a lack of material. The finding of an intrathecal immune response to several herpes viruses (H, E and C) in a further control patient with suspected cerebral vasculitis corroborates previous concerns about cross-reactivities between *Herpesviridae* (since simultaneous CNS infection with all three viruses is highly unlikely) [4]. Although a response to more than one herpes virus was relatively infrequent in the present study, the risk of cross-reactivity would argue against including more than one herpes virus in the MRZ panel. In any case, in accordance with a previous study [26], inclusion of herpes simplex virus in the panel did not result in an increase in sensitivity in the present study, nor was inclusion of EBV or CMV associated with such an increase. A positive AI for herpes simplex virus was even more common in the control than in the MS group (N=3 vs. N=1), as was a positive AI for CMV, despite the fact that not all controls could be tested for these two AIs due to a lack of material (Table 1).

Our study once more confirms the high specificity of the classical MRZ panel. It also strongly corroborates the notion of the MRZ reaction being just part of a much broader, polyspecific humoral immune response in MS. The latter notion is in accordance with the fact that antibodies to M, R and Z account only for a proportion of intrathecally produced CSF IgG [7] and are not accountable for the majority of CSF oligoclonal IgG bands in MS [31]. However, it should be underlined that there is currently no evidence that any of the viruses that form part of the MRZB or MRZBU reaction is actively involved in the aetio-pathogenesis of MS. PCR studies did not demonstrate reactivation of measles virus, rubella virus, zoster virus, parvovirus B19 or mumps virus during acute attacks [6, 19]. This is consistent with the concept that the MRZ reaction represents non-specific (‘nonsense’) B-cell activation. Its exact role in the immunopathophysiology of MS has still to be elucidated.

Of note, MS is strongly associated with EBV, with nearly 100% of patients with MS being seropositive for anti-EBV antibodies. EBV is a B lymphotropic virus, and acute EBV infection is known to lead to a strong polyspecific activation of B cells [33]. It has thus been hypothesized that polyspecific antibody producing B lineage cells may enter the CNS of patients with MS at the time of and triggered by acute EBV infection [20, 29] and that the exact composition of the intrathecally produced repertoire of antimicrobial antibodies in MS may thus mirror the presence or absence of specific B-cell clones at the very time of EBV infection (immunological ‘snapshot’). Given the delay between EBV infection and generation of anti-EBV antibodies, this would mostly include non-EBV-specific B-cell clones, which could explain why a positive EBV-AI is relatively rare in MS—as opposed to a positive AI to M, R, Z and other antigens—despite the fact that virtually all patients with MS are positive for serum antibodies to EBV [29]. The frequency of elevated EBV-AIs in patients with MS observed in the present study (13.6%) is in good accordance with the results of previous studies, which found an elevated EBV AI in in 4.3–15.6%, depending on the EBV antigen used, of adult patients with MS [29]. Of note, contact with M, R, Z, B and U, i.e., the five antigens found to be useful in the present study, usually occurs during early childhood and thus indeed prior to contact with EBV. As expected, all MS patients tested in this study were positive for serum anti-EBV antibodies; by contrast, three disease controls were seronegative.

It should not go unmentioned that other factors than panel composition may influence the frequency of a positive MRZ reaction in a given cohort: (1) It has been shown that the MRZ reaction is virtually absent in important MS mimics such as myelin oligodendrocyte glycoprotein (MOG)-IgG-positive encephalomyelitis (MOG-EM; also termed MOG antibody-related autoimmune disorder, or MOGAD) [13, 15, 16] and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) [10, 14, 17, 32], ADEM [8, 11], paraneoplastic neurological disorders [8, 9] and neuroborreliosis [1, 8]. Accidental inclusion of such patients in studies investigating the MRZR in MS will result in underestimating the marker’s sensitivity. (2) A positive MRZ reaction might be less frequent in children; while this might be due to the difference between prepubertal and postpubertal prevalence rates for rubella virus antibodies [8, 25], it may partly also reflect accidental inclusion of children with MOG-EM—a condition that is common among children with CNS demyelination (and even more common than MS in young children)—in previous pediatric studies. (3) The number of positive AIs and thus the frequency of a bi- or trispecific MRZR increased with disease duration in one study [22]. (4) Differences in MRZR frequency between various MS subtypes may play a role, given that a negative MRZ reaction was found in the few patients with histopathologically defined pattern II or pattern III MS or Baló’s concentric sclerosis analysed so far [12, 18]. These conditions are also much less frequently associated with intrathecal
total IgG synthesis (as indicated by negative OCBs and a normal CSF/serum ratio) and thus may represent entities immunopathogenetically different from classical pattern I MS [12, 18].

Parvovirus B19 is not usually considered a ‘neurotropic’ virus. However, it is important to note that the polyspecific intrathecal humoral immune response in MS is not restricted to neurotropic viruses. It has already been shown to include also antibodies to *Chlamydia pneumoniae*, both in adults and children, and to several other microbiological agents that do not typically cause CNS infection [2, 28]. Given that the research on CSF antibodies in MS was originally driven by the interest in a then supposed viral aetiology of MS, the focus on neurotropic viruses in much of the existing literature on the MRZ reaction may have historic reasons. Moreover, the frequency of the classic MRZ reaction has been shown to be linked to the individual vaccination status [27], suggesting that a history of actual CNS infection is not required. The presence of a broader panel of anti-microbial antibody responses that is not restricted to ‘neurotropic’ viruses would be in line with the notion of the MRZ reaction simply reflecting parts of the individual B cell repertoire present at the time of the first EBV infection in patients with MS [20].

### Strengths and limitations

The following potential limitations should be mentioned: (1) Some of the ELISAs used for determining AIs (B, D, P and T) in the present study are in-house assays, i.e., they have not yet been officially approved by the marketing authorities for use in CSF analytics. (2) Previous studies on the classical MRZ reaction were mostly conducted using assays manufactured by Dade Behring/Siemens, Germany, while ELISAs manufactured by Euroimmun were employed in the present study. However, regular round-robin tests performed by INSTAND e.V. (www.instand-ev.de) have shown excellent sensitivity and specificity of the assays used here compared with other MRZ assays. (3) Although the control group comprised patients with various inflammatory and non-inflammatory neurological diseases, further studies that include large numbers of patients with relevant differential diagnoses of MS will be necessary to assess the specificity of the extended MRZ panel for MS in a definite way.

### Conclusion

In summary, addition of AIs for parvovirus B19 and mumps to the classical MRZ panel (‘MRZplus’) was associated with an increase in sensitivity for MS without major loss in specificity, while inclusion of AIs to HSV, EBV, CMV, diphtheria, pertussis and tetanus did not result in an increase in sensitivity. Our study provides a rationale for larger, prospective studies on the impact of adding parvovirus B19 and mumps to the MRZ panel. Such studies should include more controls with inflammatory CNS disorders and should ideally be performed prospectively and in a multicentre setting.

**Acknowledgements** BW and SJ would like to thank Mrs. Anna Eschibeck and Mrs. Silvia Zacharevics for excellent technical assistance.

**Authors’ contributions** Idea and conception: SJ; biosampling: SJ, BW, JH; acquisition of data: DW, SJ, BW, LK; analysis of data: SJ, DW; drafting of the manuscript: SJ; revision for intellectual content: all authors.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Compliance with ethical standards**

**Conflict of interest** Sven Jarius and Jürgen Haas report no conflicts of interest. Diana Wilken and Lars Komorowski are employees of Euroimmun AG, Lübeck, Germany. Klemens Ruprecht received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BHI Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva, Roche, Novartis, and Guthy Jackson Charitable Foundation, none of which are related to the present study. Brigitte Wildemann received grants from German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation, grants and personal fees from Merck Serono, sanofi-aventis/Genzyme, Teva, Roche, Novartis, and Guthy Jackson Charitable Foundation, none of which are related to the present study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Bednarova J, Stourac P, Adam P (2005) Relevance of immunological variables in neuroborreliosis and multiple sclerosis. Acta Neurrol Scand 112:97–102
2. Derfuss T, Gurkov R, Then Bergh F, Goebels N, Hartmann M, Barz C, Wilske B, Autenrieth I, Wick M, Hohlfeld R, Meinf E (2001) Intrathecal antibody production against Chlamydia
pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 124:1325–1335

3. Derfluss T, Hohlfeld R, Meinel E (2005) Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol 252:968–971

4. Felgenhauer K, Reiber H (1992) The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig 70:28–37

5. Frederiksen JL, Sindic CJ (1998) Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler 4:22–26

6. Godec MS, Asher DM, Murray RS, Shin ML, Greenham LW, Gibb CJ Jr, Gadjusek DC (1992) Absence of measles, mumps, and rubella viral genomic sequences from multiple sclerosis brain tissue by polymerase chain reaction. Ann Neurol 32:401–404

7. Jacobi C, Lange P, Reiber H (2007) Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J Neuromunmunol 187:139–146

8. Jarius S, Eichhorn P, Franciotta D, Peteret HF, Akman-Demir G, Wick M, Wildemann B (2017) The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 264:453–466

9. Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Völz R (2009) The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity? J Neurol Sci 280:98–100

10. Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Peteret HF, Maurer M, Tumani H, Vincent A, Eichhorn P, Wildemann B, Wick M, Völz R (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neumyelitis optica. J Neurol Neurosurg Psychiatry 79:1134–1136

11. Jarius S, Franciotta D, Marchioni E, Hohlfeld R, Wildemann B, Völz R (2006) Intrathecal polyspecific immune response against neurotropic viruses discriminates between multiple sclerosis and acute demyelinating encephalomyelitis. J Neurol 253:486

12. Jarius S, Konig FB, Metz I, Ruprecht K, Paul F, Bruck W, Wildemann B (2017) Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroimmunamn 14:171

13. Jarius S, Lechner C, Wendel EM, Baumann M, Breu M, Schimmel M, Karenforst M, Marina AD, Merkenschlager A, Theis C, Blaschek A, Saldanin M, Leiz S, Leyoldt P, Pschibul A, Hackenberg A, Hahn A, Syrbe S, Strautmanis J, Hauser M, Krieg P, Eisenkolbl A, Stoffels J, Eckenweiler M, Ayzenberg I, Haas J, Hofberger R, Kleiter I, Korporal-Kuhnke M, Ringelstein M, Ruprecht K, Siebert N, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, Rostasy K, in cooperation with the Bsg, the Neuromyelitis Optica Study G (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17:261

14. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokolli K, Pache F, Stich O, Beume LA, Hummert MW, Ringelstein M, Trebst C, Winkelman A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, in cooperation with the Neuromyelitis Optica Study G (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280
28. Rostasy K, Reiber H, Pohl D, Lange P, Ohlenbusch A, Eiffert H, Maass M, Hanefeld F (2003) Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies. Neurology 61:125–128

29. Ruprecht K, Wildemann B, Jarius S (2018) Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. J Neurol 265:239–252

30. Schubert J, Weissbrich B (2007) Detection of virus-specific intrathecally synthesised immunoglobulin G with a fully automated enzyme immunoassay system. BMC Neurol 7:12

31. Sindic CJ, Monteyne P, Laterre EC (1994) The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol 54:75–80

32. Sven Jarius, Klemens Ruprecht, Ingo Kleiter, Nadja Borisow, Nasrin Asgari, Kalliopi Pitarokoili, Florence Pache, Oliver Stich, Lena-Alexandra Beume, Martin W. Hümmer, Corinna Trebst, Marius Ringelstein, Orhan Aktas, Alexander Winkelmann, Mathias Buttmann, Alexander Schwarz, Hanna Zimmermann, Alexander U. Brandt, Diego Franciotta, Marco Capobianco, Joseph Kuchling, Jürgen Haas, Mirjam Korporeal-Kuhnke, Soeren Thue Lillevang, Kai Fechner, Katherin Schanda, Friedemann Paul, Brigitte Wildemann, Markus Reindl, (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation 13 (1)

33. Thorley-Lawson DA (2015) EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol 390:151–209